Intelligence / Healthtech / New Clinical Trials / BioNTech SE
BioNTech SE
21 Oct 2026: Trial registered · A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 21 Oct 2026
- Title
- A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
- Conditions
- Advanced Solid Tumors
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07886684
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at BioNTech SE
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for BioNTech SE in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.